275 related articles for article (PubMed ID: 31188151)
1. GBA1-associated parkinsonism: new insights and therapeutic opportunities.
Ryan E; Seehra G; Sharma P; Sidransky E
Curr Opin Neurol; 2019 Aug; 32(4):589-596. PubMed ID: 31188151
[TBL] [Abstract][Full Text] [Related]
2. Glucocerebrosidase and its relevance to Parkinson disease.
Do J; McKinney C; Sharma P; Sidransky E
Mol Neurodegener; 2019 Aug; 14(1):36. PubMed ID: 31464647
[TBL] [Abstract][Full Text] [Related]
3. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
4. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ
Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096
[TBL] [Abstract][Full Text] [Related]
5. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.
Sardi SP; Clarke J; Viel C; Chan M; Tamsett TJ; Treleaven CM; Bu J; Sweet L; Passini MA; Dodge JC; Yu WH; Sidman RL; Cheng SH; Shihabuddin LS
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3537-42. PubMed ID: 23297226
[TBL] [Abstract][Full Text] [Related]
6. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
Henderson MX; Sedor S; McGeary I; Cornblath EJ; Peng C; Riddle DM; Li HL; Zhang B; Brown HJ; Olufemi MF; Bassett DS; Trojanowski JQ; Lee VMY
Neuron; 2020 Mar; 105(5):822-836.e7. PubMed ID: 31899072
[TBL] [Abstract][Full Text] [Related]
7. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.
Sardi SP; Cheng SH; Shihabuddin LS
Prog Neurobiol; 2015 Feb; 125():47-62. PubMed ID: 25573151
[TBL] [Abstract][Full Text] [Related]
8. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
9. The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.
Aflaki E; Westbroek W; Sidransky E
Neuron; 2017 Feb; 93(4):737-746. PubMed ID: 28231462
[TBL] [Abstract][Full Text] [Related]
10. Exploring the link between glucocerebrosidase mutations and parkinsonism.
Westbroek W; Gustafson AM; Sidransky E
Trends Mol Med; 2011 Sep; 17(9):485-93. PubMed ID: 21723784
[TBL] [Abstract][Full Text] [Related]
11. Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.
Sardi SP; Singh P; Cheng SH; Shihabuddin LS; Schlossmacher MG
Neurodegener Dis; 2012; 10(1-4):195-202. PubMed ID: 22327140
[TBL] [Abstract][Full Text] [Related]
12. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
[TBL] [Abstract][Full Text] [Related]
13. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
[TBL] [Abstract][Full Text] [Related]
14. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
Kim D; Hwang H; Choi S; Kwon SH; Lee S; Park JH; Kim S; Ko HS
Acta Neuropathol Commun; 2018 Apr; 6(1):32. PubMed ID: 29703245
[TBL] [Abstract][Full Text] [Related]
15. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
[TBL] [Abstract][Full Text] [Related]
16. Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review.
Gaubert S; Hourregue C; Mouton-Liger F; Millot P; Franco M; Amar-Bouaziz E; Aarsland D; Hugon J; Paquet C
Neurosci Biobehav Rev; 2022 Oct; 141():104856. PubMed ID: 36084847
[TBL] [Abstract][Full Text] [Related]
17. Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders.
Goker-Alpan O; Stubblefield BK; Giasson BI; Sidransky E
Acta Neuropathol; 2010 Nov; 120(5):641-9. PubMed ID: 20838799
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
19. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Menozzi E; Toffoli M; Schapira AHV
Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
[TBL] [Abstract][Full Text] [Related]
20. Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications.
Balestrino R; Schapira AHV
Neuroscientist; 2018 Oct; 24(5):540-559. PubMed ID: 29400127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
